个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共11条记录   Antisense Oligonucleotides for the Treatment of Dyslipidemia [作者：Gouni-Berthold, I; Berthold, HK,期刊：Current Pharmaceutical Design, 页码：950-960 , 文章类型： Review，,卷期：2011年17-9] New studies further demonstrate that lowering low-density lipoprotein (LDL)-cholesterol, at least with the use of statins, decreases the risk of cardiovascular disease (CVD). Subsequently national and international guide... Cardiovascular Disease and Dyslipidemia: Beyond LDL [作者：Poss, J; Custodis, F; Werner, C; Weingartner, O; Bohm, M; Laufs, U,期刊：Current Pharmaceutical Design, 页码：861-870 , 文章类型： Review，,卷期：2011年17-9] Low-density lipoproteins (LDL) are atherogenic and represent a strong cardiovascular risk factor. Therefore, LDL-cholesterol (LDL-C) remains the primary target in lipid lowering therapy. However, since many cardiovascula... Cardiovascular disease: Focus on Dyslipidemia [作者：Gouni-Berthold, I,期刊：Current Pharmaceutical Design, 页码：850-851 , 文章类型： Editorial Material，,卷期：2011年17-9] Lipid Management for the Prevention of Cardiovascular Disease [作者：Schaefer, JR,期刊：Current Pharmaceutical Design, 页码：852-860 , 文章类型： Review，,卷期：2011年17-9] Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are m... Lipid-lowering Drug Therapy in Elderly Patients [作者：Berthold, HK; Gouni-Berthold, I,期刊：Current Pharmaceutical Design, 页码：877-893 , 文章类型： Review，,卷期：2011年17-9] Coronary heart disease (CHD) is the leading cause of death among elderly patients and >80% of all coronary deaths occur in patients > 65 years. Cerebrovascular events are also associated with older age. Since elevated ch... Lipoprotein(a): Medical Treatment Options for an Elusive Molecule [作者：Parhofer, KG,期刊：Current Pharmaceutical Design, 页码：871-876 , 文章类型： Review，,卷期：2011年17-9] Elevated levels of lipoprotein(a) are causally related to premature atherosclerosis. It is therefore of interested to evaluate by which treatment modalities elevated lipoprotein(a) levels can be decreased. With the excep... New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors [作者：Rizzo, M; Wierzbicki, AS,期刊：Current Pharmaceutical Design, 页码：943-949 , 文章类型： Review，,卷期：2011年17-9] Microsomal triglyceride transfer protein (MTP) is involved in the synthesis of very low density lipoprotein in the liver. Its deficiency results in abetalipoproteinemia. MTP inhibitors target the assembly and secretion o... Plant Sterols and Stanols in the Treatment of Dyslipidemia: New Insights into Targets and Mechanisms Related to Cardiovascular Risk [作者：Baumgartner, S; Mensink, RP; Plat, J,期刊：Current Pharmaceutical Design, 页码：922-932 , 文章类型： Review，,卷期：2011年17-9] Plant sterols and stanols are naturally occurring constituents of plants and as such normal components of our daily diet. The consumption of foods enriched in plant sterols and stanols may help to reduce low-density lipo... Dyslipidemia Treatment and Cardiovascular Disease in the Renal Patient [作者：Burst, V; Benzing, T,期刊：Current Pharmaceutical Design, 页码：894-907 , 文章类型： Review，,卷期：2011年17-9] Cardiovascular disease is the most prevalent cause of death in patients with chronic kidney disease (CKD), even at an early stage of the disease and is considered a coronary heart disease risk equivalent. Therefore, ther... The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond [作者：Economou, F; Xyrafis, X; Christakou, C; Diamanti-Kandarakis, E,期刊：Current Pharmaceutical Design, 页码：908-921 , 文章类型： Review，,卷期：2011年17-9] Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome characterized by oligo-or anovulation, clinical and/or biochemical signs of hyperandrogenemia and polycystic ovaries. Clinical expression is determined by both... The Role of Vitamin D in Dyslipidemia and Cardiovascular Disease [作者：Zittermann, A; Gummert, JF; Borgermann, J,期刊：Current Pharmaceutical Design, 页码：933-942 , 文章类型： Review，,卷期：2011年17-9] Dyslipidemia and vascular calcification are important predictors of cardiovascular disease (CVD). Vitamin D may have an influence on these two CVD risk markers. We performed a systematic review on vitamin D, dyslipidemia...